The Advanced Approval Pathway for Longevity Medicines (AAPLM) aims to incentivize the development of longevity therapies by aligning economic benefits with public health improvements. This pathway includes three key provisions: (1) a faster approval process for longevity medicine, (2) transferable Priority Review Vouchers (PRVs), and (3) patent extensions granted on a per-indication basis. These incentives allow companies to bring therapies to market more quickly, improve financial stability through voucher sales, and increase asset value for investors through patent extensions, supporting broader, longer-term clinical development and trials for age-related diseases.

By signing this petition, you support the creation of the Advanced Approval Pathway for Longevity Medicines (AAPLM) that will help companies accelerate their developments and approvals of therapies targeting aging and age-related multi-morbidities, expanding access to innovative treatments. Together, we can advance public health, enhance quality of life, and drive economic growth by fostering groundbreaking solutions to the challenges of aging.